Biocept, Inc. (BIOC)

4.4100 +0.1300 (+3.04%) At close: 4:00PM EDT

Biocept, Inc.

9955 Mesa Rim Road
San Diego, CA 92121
United States
858 320 8200
http://biocept.com

Sector(s): Healthcare
Industry: Diagnostics & Research
Full Time Employees: 104

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Michael W. Nall	CEO, Pres & Director	598.56k	N/A	1963
Mr. Timothy C. Kennedy	CFO, COO & Corp. Sec.	460.59k	N/A	1958
Dr. Soon Kap Hahn Ph.D.	Founder	N/A	N/A	N/A
Mr. Pavel Tsinberg	Director of Technology Devel.	N/A	N/A	N/A
Mr. Michael W. Brown	Gen. Counsel and Compliance & Privacy Officer	N/A	N/A	N/A
Mr. David S. Moskowitz R.Ph., MBA	VP of Strategy & Corp. Communications	N/A	N/A	N/A
Mr. Michael Terry	Sr. VP of Corp. Devel.	N/A	N/A	1955
Ms. Brenda Tang	Sr. Director of Marketing	N/A	N/A	N/A
Mr. Gary Marchetti	Sr. Director of People & Culture/Facilities	N/A	N/A	N/A
Dr. Veena M. Singh	Sr. Medical Director	N/A	N/A	1975

Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Biocept, Inc., an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating tumor nucleic acid assays utilizing a standard blood sample. Its cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring in order to identify resistance mechanisms. The company offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer, gastric cancer, colorectal cancer, prostate cancer, melanoma, pancreaticobiliary cancer, and ovarian cancer. Its Target-Selector molecular technology enables detection of mutations and genome alterations with enhanced sensitivity and specificity, as well as is applicable to nucleic acid from circulating tumor DNA; and Target-Selector CTC and molecular platforms provide biomarker detection and monitoring capabilities. In addition, it offers laboratory services to medical oncologists, neuro-oncologists, surgical oncologists, urologists, pulmonologists, pathologists, and other physicians. Further, it is developing PCR-based assays for detecting the COVID-19 virus. The company sells its cancer diagnostic assays directly to oncologists and other physicians at private and group practices, hospitals, laboratories, and cancer centers in the United States, as well as markets its clinical trial and research services to pharmaceutical and biopharmaceutical companies, and clinical research organizations. Biocept, Inc. was founded in 1997 and is headquartered in San Diego, California.

Corporate Governance

Biocept, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.